Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of a
single IV dose of GLYX-13, an N-Methyl-D-aspartate (NMDA) receptor glycine site functional
partial agonist, in normal, healthy human volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Naurex, Inc Naurex, Inc, an affiliate of Allergan plc